all things to do with diabetes obesity and metabolism
10th October 2026, A/Prof Chee L Khoo
The topline results of TRANSCEND-T2D 1 were released in March 2026 and the full results have since been published. It was a trial involving patients with sub-optimally controlled T2D and obesity with the primary aim of better glycaemic control. The TRIUMPH series were designed to primarily demonstrate the efficacy of retatrutide in weight management in patients with obesity +/- T2D and a variety of clinical conditions (see Table 1).…
5th September, A/Prof Chee L Khoo and A/Prof Shannon Lin
Diabetes-related sarcopenia, characterised by the loss of muscle mass, strength, and function in people with diabetes, is an emerging but under-recognised complication associated with falls, frailty, hospitalisations, and reduced quality of life. I am working closely with researchers at the University of Technology Sydney (UTS) and we are conducting a short survey to understand health professionals’ awareness, knowledge, and current practices relating to diabetes-related sarcopenia.…
29th August 2026, A/Prof Chee L Khoo
The European Society of Endocrinology clinical practice guideline for evaluation and management of menopause and the perimenopause recommend that a holistic approach is taken for women during perimenopause and menopause, not having a sole focus on hormone replacement therapy (HRT)/ menopausal hormone therapy (MHT) (1). It recognised that these women can be appropriately managed in primary care according to recognised guidelines.…
28th August 2026, A/Prof Chee L Khoo
Atherosclerotic cardiovascular disease (ASCVD) is considered an inflammatory condition. Not only is inflammation central to the initiation of ASCVD, it is also responsible for the progression as well as the destabilisation of atherosclerotic plaque leading to ischaemia. This is in addition to the other well known risk factors (e.g. dyslipidaemia, smoking, hypertension etc) for ASCVD.…
13th August 2026, A/Prof Chee L Khoo
We know (maybe better phrased – we think we know) that it is the amyloid-β (Aβ) plaques that are a key driver of pathological processes in Alzheimer’s disease (AD) (1,2). Targeting the Aβ should then prevent or at the very least delay the progression of the dementia. The problem with prevention is that we don’t know who are going to get dementia till there is some cognitive impairment.…
25th July 2026, A/Prof Chee L Khoo
We know that 55-65% patients with type 2 diabetes (T2D) have metabolic dysfunction associated fatty liver disease (MAFLD) (1). We also know that 28% of patients with MAFLD will develop T2D if not already present by the time MAFLD is detected (2). There is emerging evidence that there are profound alterations in oral glucose handling in individuals with MAFLD even before T2D is diagnosed.…
30th June 2026, A/Prof Chee L Khoo
We have waited for a very long time. We only have one second generation long-acting basal insulin even though degludec have been available overseas for ≥ 10 years now. Insulin degludec (iDeg), in combination with a prandial insulin (insulin aspart) has been available in Australia as Ryzodeg® since 2018. But iDeg on its own?…
28th June 2026, A/Prof Chee L Khoo
It’s all over the news. Teplizumab (Tzield) has just been approved by the Australian Therapeutic Goods Administration (TGA) delay the onset of Stage 3 type 1 diabetes mellitus (T1D) in adult and paediatric patients aged 8 years and older with Stage 2 type 1 diabetes mellitus (1). Wow. But what does that mean for our patients already with T1D or those who are at very high risk of developing T1D?…
10th June 2026, A/Prof Chee L Khoo
We know that if a woman developed gestational diabetes mellitus (GDM), the risk of development of type 2 diabetes (T2D) later in life increases by 4-10 times. We also know that the same woman also have higher risk of developing elements of cardiovascular disease (CVD) including hypertension, atherosclerotic CVD ASCVD and heart failure (HF).…
23rd May 2026, A/Prof Chee L Khoo
We all know about the causal association between the so called bad cholesterol, LDL-cholesterol (LDL-C) and atherosclerotic cardiovascular disease (ASCVD). There are suggestions that apolipoprotein B (apoB) levels might be a better reflection of atherosclerotic burden. There is now emerging consensus that relying on particle number whether with LDL-C or apoB is rather too simplistic.…
25th April 2026, A/Prof Chee L Khoo
When we think about diabetes, we think about the shrinkage of beta cell mass and its inability to keep up with the insulin demand. We have lots of information of what the islet cells can or cannot do in diabetes but we don’t actually know much of pathogenesis of the pancreatic endocrine (or exocrine) dysfunction in diabetes.…
24th April 2026, A/Prof Chee L Khoo
Australian and international guidelines recommend 150– 300 min of moderate physical activity (MPA), 75–150 min of vigorous physical activity (VPA), or a combination of both per week (1,2). Some people prefer slower but longer exercises while other prefer more intense for shorter periods of time. There is data suggesting that VPA leads to superior improvements in cardiorespiratory fitness, functional capacity, and several cardiometabolic risk factors compared to lower-intensity activities at equivalent volumes (3-5).…